Year: 2023

eQ Plc interim report24 October 2023, at 8:00 AM January to September 2023 in briefThe Group’s net revenue during the period was EUR 52.3 million (EUR 64.2 million from 1 Jan. to 30 September 2022). The Group’s net fee and commission income was EUR 51.5 million (EUR 62.8 million). The Group’s operating profit fell by 24% to EUR 30.0 million (EUR 39.5 million). The Group’s profit was EUR 23.8 million (EUR 31.4 million). The consolidated earnings per share were EUR 0.59 (EUR 0.79). The net revenue of the Asset Management segment decreased by 14% to EUR 50.3 million (EUR 58.6 million) and the operating profit by 17% to EUR 31.7 million (EUR 38.4 million). The management fees of the Asset Management segment grew by 2 per cent to EUR 46.8 million (EUR 45.6 million) and the performance fees fell by 71 per cent to EUR 3.9 million (EUR...

October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Tuesday, October 31, 2023 at 1:30 pm CET (8:30 am ET) to discuss its third quarter 2023 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call. Belgium                32 800 50 201France                        33 800 943355Netherlands                31...

In Q3 of this year, AS LHV Group earned EUR 39.5 million in net profit. AS LHV Pank earned EUR 36.0 million in net profit, LHV Bank Limited EUR 3.2 million, AS LHV Varahaldus EUR 0.6 million, and AS LHV Kindlustus EUR 0.3 million. The return on equity attributable to the Group’s shareholders was 31.6% in Q3. In Q3 of 2023, the Group generated consolidated revenue of EUR 81.5 million, i.e., 9% more than in the previous quarter. Of the revenue, net interest income accounted for EUR 68.1 million, and net fee and commission income for EUR 13.6 million. The operating expenses of the consolidation group amounted to EUR 32.8 million in Q3, i.e., 1% less than in Q2. Net profit for the quarter was EUR 3.8 million more than in the previous quarter (+11%) and 3.7 times higher than in the same period last year. As at the end of September, LHV Group’s...

Borregaard’s operating revenues were NOK 1,714 million (NOK 1,752 million)2 in the 3rd quarter of 2023. EBITDA1 increased to NOK 482 million (NOK 434 million). BioMaterials and Fine Chemicals had result improvements while BioSolutions had a decrease compared with the 3rd quarter of 2022. In BioSolutions, higher sales prices and reduced energy costs were more than offset by reduced sales volume, lower contribution from traded vanillin products and cost inflation in general. Lower energy costs and higher sales prices were the main reasons for the EBITDA improvement in BioMaterials. The increased result in Fine Chemicals was mainly due to increased sales prices for bioethanol. The net currency effects were positive in all areas. The proposed reduction in the Norwegian CO2 compensation scheme will impact Borregaard’s EBITDA1 for 2023 by approximately...

(Oslo, 24 October 2023) Hexagon Purus, a world leading manufacturer of zero emission mobility and infrastructure solutions, has received purchase orders for the delivery of hydrogen fuel storage systems to Solaris, a leading European bus manufacturer, worth approximately EUR 6.4 million. The purchase orders can be viewed in conjunction with the previously announced long-term supply agreement with Solaris in November 2021. Hexagon Purus’ hydrogen fuel storage systems will be used to support Solaris’ roll-out of hydrogen fuel-cell electric buses in Europe following recent public tender win in Bologna, Italy. Since 2021, Hexagon Purus has delivered hydrogen fuel storage systems for close to 200 Solaris hydrogen fuel-cell electric buses.     Driving Energy Transformation “Solaris is a leading player in driving the zero-emission transition...

Territorial expansion for a product candidate previously exclusively targeting the U.S. Kye Pharmaceuticals to register and commercialize in CanadaLiège, Belgium – 24 October 2023 – 7AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces it has out-licensed its product candidate atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder (ADHD) in Canada to Kye Pharmaceuticals. ADHD is one of the most common neurobehavioral disorders, affecting 4-6% of adults and 5-7% of children in Canada, or approximately 1,8 million Canadians1. It is a chronic condition for most patients, with approximately 60 to 80% of the symptoms of ADHD persisting...

Ad hoc announcement pursuant to Art. 53 LRTransformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing operations2 Q3 sales grew +12% (cc, +12% USD) with core operating income growing +21% (cc, +17% USD)Growth driven by continued strong performance from Kesimpta (+124% cc), Entresto (+31% cc), Kisqali (+76% cc), Pluvicto (+217% cc) and Scemblix (+157% cc)Q3 operating income grew +13% (cc, -4% USD) driven by higher sales and lower restructuring charges, partly offset by higher impairments through discontinuation of early stage development projects Q3 net income grew +37% (cc, +14% USD) mainly due to higher operating income Q3 free cash flow3 was USD 5.0 billion (+24% USD) driven by higher net cash flows from operating activities Q3 core EPS grew +29%...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023. Business highlightsTransaction with Sosei Heptares (hereafter referred as the “Sosei Deal”): Idorsia sold its Asia Pacific (ex-China) operations on July 20 – including selected license rights to products – for a total consideration of CHF 400 million. Cost reduction initiative targeting a reduction of the fixed cost base at headquarters by approximately 50% expected to become fully effective in early 2024. Management change in the US: Tausif ‘Tosh’ Butt joined as President and General Manager of Idorsia US in September 2023. Aprocitentan: Worldwide rights reacquired from Janssen – agreement now effective following clearance by US antitrust authorities.Commercial...